Equities analysts predict that Nektar Therapeutics (NASDAQ:NKTR) will announce sales of $36.49 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $26.67 million and the highest is $47.90 million. Nektar Therapeutics posted sales of $32.77 million during the same quarter last year, which would indicate a positive year over year growth rate of 11.4%. The business is scheduled to issue its next earnings report on Wednesday, August 2nd.

On average, analysts expect that Nektar Therapeutics will report full-year sales of $36.49 million for the current year, with estimates ranging from $139.54 million to $258.02 million. For the next year, analysts forecast that the company will post sales of $176.29 million per share, with estimates ranging from $110.70 million to $226.41 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.02. The business had revenue of $24.73 million for the quarter, compared to the consensus estimate of $29.43 million. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. Nektar Therapeutics’s quarterly revenue was down 58.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.14) earnings per share.

NKTR has been the topic of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research report on Monday, June 26th. Jefferies Group LLC set a $25.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Saturday, April 22nd. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Roth Capital set a $31.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 11th. Finally, BidaskClub upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Nektar Therapeutics presently has a consensus rating of “Buy” and an average target price of $26.29.

Nektar Therapeutics (NASDAQ:NKTR) traded down 1.17% during trading on Thursday, hitting $22.85. The company’s stock had a trading volume of 526,230 shares. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The firm has a 50 day moving average of $19.98 and a 200 day moving average of $17.75. The firm’s market cap is $3.55 billion.

In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $19.55, for a total value of $33,254.55. Following the sale, the senior vice president now directly owns 32,803 shares of the company’s stock, valued at $641,298.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Ivan P. Gergel sold 54,920 shares of the business’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total value of $1,158,812.00. Following the completion of the sale, the senior vice president now directly owns 98,492 shares in the company, valued at $2,078,181.20. The disclosure for this sale can be found here. Insiders sold 159,803 shares of company stock worth $3,328,247 over the last three months. Corporate insiders own 6.10% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the company. Flinton Capital Management LLC increased its stake in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the period. State of Alaska Department of Revenue increased its stake in Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 460 shares during the period. Louisiana State Employees Retirement System increased its stake in Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after buying an additional 500 shares during the period. LS Investment Advisors LLC increased its stake in Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the period. Finally, Municipal Employees Retirement System of Michigan increased its stake in Nektar Therapeutics by 1.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 34,920 shares of the biopharmaceutical company’s stock valued at $820,000 after buying an additional 570 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/27/nektar-therapeutics-nasdaqnktr-expected-to-post-quarterly-sales-of-36-49-million.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.